Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting

Table 1 Number of people in each age group and their distribution into risk groups

	Number of people	Percentage of people in each age and risk group
Age		Low risk	At risk	High risk
18–49 years	2,291,376	80.10%	19.71%	0.19%
50–64 years	995,487	59.86%	39.93%	0.21%
65–74 years	528,795	42.16%	57.73%	0.11%
75–84 years	273,257	30.05%	69.87%	0.08%
85–99 years	115,710	37.45%	62.50%	0.05%

Note: Risk groups refer to an individual’s risk of pneumococcal diseases based on the presence of underlying chronic conditions. Low risk refers to adults with no underlying chronic conditions. At risk refers to immunocompetent adults with underlying chronic condition and immunocompromised adults, who are not currently included in the Norwegian blue prescription (“blå resept”). High risk refers to immunocompromised adults who are currently included in the blue prescription. Sources: [21, 23]

ISSN: 1478-7547